Related references
Note: Only part of the references are listed.Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
Jie Ling et al.
ANTI-CANCER DRUGS (2008)
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP (TM)) predicts in vivo metabolic inhibition
Ashok Rakhit et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
MD Prados et al.
NEURO-ONCOLOGY (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
AB Lassman et al.
CLINICAL CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor antagonists: Novel therapy for the treatment of high-grade gliomas
N Nathoo et al.
NEUROSURGERY (2004)
Share Paper
